Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04526834 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Study acronym: CERTAIN
StatusActive, Not Recruiting
PhasePhase 1
Started2021-09-08
View on ClinicalTrials.gov ↗
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma

Amendment record

Amended 9 times since 2020-08-25; most recent filed 2023-04-18. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2023-04-18
Amendment Study Status v9
2022-11-21
Amendment Study Status v8
2022-07-21
Amendment Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v7
2021-10-04
Amendment Study Status v6
2021-03-15
Amendment Study Status, Contacts/Locations v5
2021-03-05
Amendment Study Status v4
2021-02-10
Amendment Study Status, Contacts/Locations v3
2021-01-31
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2020-10-21
Amendment Study Status, Contacts/Locations v1
2020-08-25
Original filing
Trial Details
NCT Number NCT04526834
Lead Sponsor Tessa Therapeutics
Conditions Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Enrollment 21 participants
Start Date 2021-09-08
Primary Completion 2022-11-22 (estimated)
Study Completion 2036-03 (estimated)
Updated on ClinicalTrials.gov 2023-04-20